Drug Discovery Featured Articles & Applications

31. Tevogen Bio, BioCentriq Team Up To Manufacture T-Cell Therapy For COVID-19 3/23/2021

    Tevogen Bio recently announced its partnership with BioCentriq, a New Jersey-based cell and gene therapy development and manufacturing center, to support clinical manufacturing of Tevogen’s investigational COVID-19 treatment. 

32. How Computational Drug Discovery Is Disrupting Biopharma 3/12/2021

    NeuBase Therapeutics CEO Dr. Dietrich Stephan discusses the important role computational drug discovery plays as we emerge from what he characterizes as “a decades-long, multi-billion-dollar chemical engineering escapade with a very low success rate to find one drug.”

33. Inside Omega Therapeutics’ Epigenomic Controllers™ 12/1/2020

    Omega Therapeutics is developing novel engineered and modular therapeutics, called Omega Epigenomic Controllers™, that are designed to target with high specificity and downregulate or upregulate the level of expression of any of the 25,000+ human genes, individually or collectively, with controlled durability, to treat and potentially cure disease.

34. Are Dry Powder Biologics Ready For Primetime? 9/21/2020

    A new approach to freezing biopharmaceuticals into fine, dry powders holds promise for flexible therapeutic form factors, efficacy improvements, and supply and distribution chain efficiencies. It's a particularly timely development in the age of COVID-19.

35. Mechanistic Action: Genesis Of A Biologics Pipeline? 6/17/2020

    Cue Biopharma President & CSO Anish Suri, Ph.D. tells us why a partnership with The University Of Oxford to visualize the mechanistic action of molecules at the immunological synapse could provide insights that guide future drug discovery and development strategy.

36. Precision Medicine In Practice 6/16/2020

    Precision medicine is bringing biopharma closer to the patient. The Christ Hospital Health Network Director Of Precision Medicine Dr. Burns Blaxall discusses why clinical-level practitioners are the key link between biopharmas and patients, and how AI is helping to define the practice.

37. A New Cost Paradigm For CAR Cell Therapies? 6/12/2020

    Hear from Acepodia CEO Sonny Hsiao about his company's claims that its proprietary approach to conjugating novel natural killer cells could reduce the cost of cellular therapeutics.

38. COVID-19 & The Virtual Trial Rush: Front-Line Insights 5/19/2020

    The COVID-19 pandemic caught many sponsor companies and sites unprepared. Clinical trial participants were told to stay home for their own safety and to relieve the burden on site personnel. For companies that had millions invested in trials that required data from those patients, panic set in and the rush was on for new technology solutions.

39. Refocusing R&D to Address Patient Care Needs During COVID-19 Uncertainty 4/9/2020

    Refocusing R&D strategies towards diagnostics and considering industry partnerships should be key considerations when developing enterprise risk plans during a crisis like COVID-19. 

40. Using Quality Tools To Build A Cohesive R&D Environment 12/15/2017

    Developing products in the life sciences industries is complex. Basic quality tools can be used to streamline the development strategy. These tools can help identify your primary goals and assess potential risks and failure modes to enable agile thinking early in development, where experimental outcomes often indicate the need to alter your development strategy.